BiomX, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details)

Commitments and Contingencies (Details) ₪ in Thousands, $ in Thousands			1 Months Ended									12 Months Ended
	Apr. 30, 2019 USD ($)	Dec. 31, 2017 USD ($)	Jun. 23, 2023 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2023 ILS (₪)	Mar. 31, 2022 USD ($)	Mar. 31, 2022 ILS (₪)	Aug. 31, 2021 USD ($)	Aug. 31, 2021 ILS (₪)	Mar. 31, 2021 USD ($)	Mar. 31, 2021 ILS (₪)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 ILS (₪)	Dec. 31, 2022 USD ($)
Commitments and Contingencies (Details) [Line Items]
Aggregate budget				$ 3,164	₪ 11,283	$ 4,094	₪ 13,004	$ 1,778	₪ 5,737	$ 3,286	₪ 10,879
Aggregate revised budget										$ 2,118	₪ 6,753
Percentage of approved budgets				30.00%	30.00%	30.00%	30.00%	50.00%	50.00%	30.00%	30.00%
Received amount of programs \| ₪													₪ 5,289
Received amount												$ 395	1,365
Total approved grants												9,353	32,068
Total grants received												8,003	₪ 27,423
Total grants subject to royalties												7,413
Total contingent obligation												7,941
Pay annual license fees		$ 25										10
Contingent Consideration Classified as Equity, Fair Value Disclosure												155		$ 148
Revenue regulatory milestones	$ 32,100	32,100
Pay License Issue Fee	20
Other liabilities														40
Research and development expenses												$ 40
Received fees			$ 1,411
Collaboration agreement, description												The fees will be paid in instalments of $500 within 30 days of the Effective Date and three additional installments of $500, $200 and $211 upon completion of certain activities under the research plan. Unless terminated earlier, this agreement will remain in effect until (a) a period of eighteen (18) months thereafter or (b) completion of the project plan and submission and approval of the final report, whichever occurs sooner, unless otherwise extended. The consideration is recorded as a reduction of R&D expenses, net in the consolidated statements of operations according to the input model method on a cost-to-cost basis. The remainder of the consideration is recorded as other accounts payable in the consolidated balance sheets.	The fees will be paid in instalments of $500 within 30 days of the Effective Date and three additional installments of $500, $200 and $211 upon completion of certain activities under the research plan. Unless terminated earlier, this agreement will remain in effect until (a) a period of eighteen (18) months thereafter or (b) completion of the project plan and submission and approval of the final report, whichever occurs sooner, unless otherwise extended. The consideration is recorded as a reduction of R&D expenses, net in the consolidated statements of operations according to the input model method on a cost-to-cost basis. The remainder of the consideration is recorded as other accounts payable in the consolidated balance sheets.
Research and development expenses												$ 16,698		16,244
Minimum [Member]
Commitments and Contingencies (Details) [Line Items]
Royalties rate												3.00%	3.00%
Annual license fees	15
Maximum [Member]
Commitments and Contingencies (Details) [Line Items]
Royalties rate												3.50%	3.50%
Annual license fees	$ 25
IIA [Member]
Commitments and Contingencies (Details) [Line Items]
Received amount of programs												$ 577	₪ 1,912
Received amount												768	₪ 783
IIA [Member]
Commitments and Contingencies (Details) [Line Items]
Received amount of programs												1,622
JSR Corporation [Member]
Commitments and Contingencies (Details) [Line Items]
Pay annual license fees		$ 15
Boehringer Ingelheim International GmbH [Member]
Commitments and Contingencies (Details) [Line Items]
Received consideration												1,200
Research and development expenses												$ 1,124		$ 287